Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $49 from $58 and keeps a Buy rating on the shares. The firm said its 1Q26 report was largely uneventful following recent Phase 3 topline data readout for lonvo-z in HAE.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
- Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
- Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
- Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline
- Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today